Abstract:
“China’s pharmaceutical environment, characterized by fragmented regulation and perverse market incentives, faces many challenges including problems with drug quality, access and affordability; irrational medicine use; and high drug prices. However, as the second world’s largest market by value, there are many opportunities to create a pharmaceutical industry capable of providing affordable quality medicines for its people and the world.”
The paper investigates the relevant regulatory environment, as well as business opportunities and challenges related to the Chinese pharmaceutical industry. An overall market assessment analysis and some investment proposals adopting the case of the Italian biopharmaceutical company Dompé are also outlined.
